Survival After Recurrent Nonsmall-Cell Lung Cancer After Complete Pulmonary Resection

Sugimura, Hiroshi; Nichols, Francis C.; Yang, Ping; Allen, Mark S.; Cassivi, Stephen D.; Deschamps, Claude; Williams, Brent A.; Pairolero, Peter C.

doi:10.1016/j.athoracsur.2006.08.046

Cited by 269 publications

(257 citation statements)

References 24 publications

Supporting

Mentioning

240

Contrasting

Unclassified

Order By: Relevance

“…The survival rates of patients with recurrence is low (nearly 50% one-year survival and 20% two-year survival). The worsening of survival is more remarkable in patients who develop systemic recurrence (49,(51)(52)(53).…”

Section: S48mentioning

confidence: 99%

“…The prevalence of recurrence increases with advanced stage [49]. When all cases who have undergone resection are considered, local, regional or systemic recurrence is seen almost in half of patients (49). Recurrence most commonly occurs in the same hemithorax (50% of cases) and second most commonly in the other hemithorax (49).…”

Section: S48mentioning

confidence: 99%

Section: S48mentioning

confidence: 99%

“…Surgical treatment of metachronous lung cancer depends on the side of the newly developed tumor, the extent thereof, the surgical procedure performed for the first tumor, and the patient's pulmonary function capacity (5). Resection can be performed in 65% of the cases, wherein one-third of the patients that undergo resection receive sub-lobar resection (49). The 5-year survival rate is 20% in all patients who have metachronous lung cancer, whereas the average 5-year survival rate in patients who undergo resection is 36% (20-50) (2, 5).…”

Section: Metachronous Lung Cancermentioning

confidence: 99%

“…When all cases who have undergone resection are considered, local, regional or systemic recurrence is seen almost in half of patients (49). Recurrence most commonly occurs in the same hemithorax (50% of cases) and second most commonly in the other hemithorax (49). The risk of recurrence is the highest in the first year after surgery and decreases in the following years (51).…”

Section: S48mentioning

confidence: 99%

See 4 more Smart Citations

Synchronous, Metachronous or Metastases?

Kocatürk¹

2018

Eur J Ther

View full text Add to dashboard Cite

Multiple primer lung cancer (MPAK) satellite tumors (accessory tumor of the same type with the same tumor in the same lobe) synchronous tumors (at the time of diagnosis, or at the same site within 3 months or with other tumors in the opposite lung) and metachronous tumors (a newly developed tumor in a patient with a definitively treated tumor). Satellite tumors are synchronous tumors also. It may be difficult to understand whether MPAC is primer tumors originating from different areas of the lung, or whether they are metastases from each other. If the histopathological types of the tumors are different from each other, it can be said that they are generally MPAK. However, if histopathological types are the same, histopathological, molecular, genetic and clinical data are needed. It is useful to demonstrate histopathologically that the detailed analysis of tumors (subtype, dominant type, especially in adenocarcinomas) and carcioma insitu background. Genetic and molecular tests are still a matter of debate. It is both very expensive and can be performed in a small number of centers, and not at the expected activity. Because the cancer cells are very complex and constantly undergoing mutation and change. The clinical criteria, especially the Martini-Melamed criteria have been used for a long time. It is still valid. If the histopathological types are different for metachronous tumors, there is no problem, but if they are the same, the second tumor is defined according to the development time. However, it may be more accurate to evaluate these patients independently from time to time. The best survival data is obtained with surgery even if it is second cancer or local recurrence or metachronous cancer Therefore, if patients with synchronous or metachronous cancer are considered to have no distant metastasis or mediastinal involvement, surgical treatment should be the priority.

show abstract

Section: S48mentioning

confidence: 99%

Section: S48mentioning

confidence: 99%

Section: S48mentioning

confidence: 99%

Section: Metachronous Lung Cancermentioning

confidence: 99%

Section: S48mentioning

confidence: 99%

See 3 more Smart Citations

Synchronous, Metachronous or Metastases?

Kocatürk¹

2018

Eur J Ther

View full text Add to dashboard Cite

show abstract

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Background: The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define the cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal tissue biopsies. SPRING is the first trial to assess a SIMS-based tri-therapy regimen in advanced non-small cell lung cancer (NSCLC). Methods: Patients with advanced NSCLC (no EGFR, ALK, or ROS1 alterations; PD-L1 unrestricted; ≤2 prior therapy lines) received avelumab, axitinib, and palbociclib (3 + 3 dose escalation design).

show abstract

Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States

Sharma¹,

Ogale²,

Smith³

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Recurrence of early‐stage non‐small cell lung cancer (eNSCLC) is associated with significant mortality and costs. Atezolizumab (ATZ) was recently approved as adjuvant treatment following resection and platinum‐based chemotherapy for adults with stage II‐IIIA NSCLC with PD‐L1 expression ≥1% after demonstrating significant improvement in disease‐free survival (DFS) relative to best supportive care (BSC) in the IMpower010 trial (NCT02486718). This study evaluated the population‐level impact of ATZ as adjuvant treatment for eNSCLC in the United States by estimating the number and costs of recurrences avoided. Methods A Monte Carlo simulation model estimated the cumulative number of recurrences and deaths prevented, along with direct, indirect, and terminal care costs, by treating eNSCLC patients with ATZ compared to BSC. The model included eligible patients treated in any given year and followed over a 5‐year period. Recurrence and mortality rates and costs were based on the IMpower010 data and supplemented by estimates from published literature. Results An estimated 4400 eNSCLC patients in the United States were eligible for adjuvant ATZ in any given year, of whom 2387 would experience recurrence within 5 years with BSC. Following the introduction of ATZ, 1030 (95% confidence interval [CI]: 1023, 1036) recurrences and 369 (95% CI: 362, 376) deaths would be avoided with estimated reductions in cumulative recurrence‐related direct, indirect, and terminal care costs of $785 million, $15 million, and $32 million, respectively, over a 5‐year time horizon. Conclusions Adjuvant ATZ is estimated to prevent a significant number of recurrences and reduce the economic burden of eNSCLC.

show abstract

Survival After Recurrent Nonsmall-Cell Lung Cancer After Complete Pulmonary Resection

Cited by 269 publications

References 24 publications

Synchronous, Metachronous or Metastases?

Synchronous, Metachronous or Metastases?

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer

Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States

Contact Info

Product

Resources

About